Wire · opportunities
BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's.
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 July 2026 · Fusion42 review
Bristol Myers Squibb is expanding its AI supercomputer to eight Vera Rubin racks (576 GPUs) after saturating its existing 2024 system, making it the first life-sciences company to deploy NVIDIA's latest-generation Rubin architecture at scale. The move follows similar announcements from Eli Lilly and Roche, though BMS's system claims superior energy efficiency per megawatt and roughly 10x the inference throughput per watt of prior-generation Blackwell chips.
This Wire brief sits within Fusion42's coverage of Digital Health, and 3 sources have reported it between 21 Jul 2026 and 27 Jul 2026.
◆ ◆ The Wire takeaway
BMS just proved it can afford to replace a saturated $100m+ compute cluster every two years. If you sell software, assays, or data to drug hunters, your margin depends on running on Rubin-class hardware now—the old kit is orphaned. If you sell to BMS's competitors, the clock is running: Lilly and Roche both have newer systems deployed, and the next generation will be live by 2027.
◆ Coverage
3 sources · first reported 21 Jul 2026 · latest 27 Jul 2026
◆ Related on Wire
◆ Topics